These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11706057)

  • 1. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer.
    Nielsen BS; Sehested M; Duun S; Rank F; Timshel S; Rygaard J; Johnsen M; Danø K
    Lab Invest; 2001 Nov; 81(11):1485-501. PubMed ID: 11706057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
    Nielsen BS; Sehested M; Timshel S; Pyke C; Danø K
    Lab Invest; 1996 Jan; 74(1):168-77. PubMed ID: 8569179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
    Nielsen BS; Rank F; Illemann M; Lund LR; Danø K
    Int J Cancer; 2007 May; 120(10):2086-95. PubMed ID: 17290405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
    Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
    Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells.
    Schnack Nielsen B; Rank F; Engelholm LH; Holm A; Danø K; Behrendt N
    Int J Cancer; 2002 Apr; 98(5):656-64. PubMed ID: 11920633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
    Holst-Hansen C; Low JA; Stephens RW; Johnson MD; Carmeliet P; Frandsen TL; Brünner N; Dickson RB
    Breast Cancer Res Treat; 2001 Aug; 68(3):225-37. PubMed ID: 11727959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.
    Rømer J; Pyke C; Lund LR; Eriksen J; Kristensen P; Rønne E; Høyer-Hansen G; Danø K; Brünner N
    Int J Cancer; 1994 May; 57(4):553-60. PubMed ID: 8181859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
    Rønne E; Høyer-Hansen G; Brünner N; Pedersen H; Rank F; Osborne CK; Clark GM; Danø K; Grøndahl-Hansen J
    Breast Cancer Res Treat; 1995 Mar; 33(3):199-207. PubMed ID: 7749147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
    Hildenbrand R; Leitz M; Magdolen V; Luther T; Albrecht S; Graeff H; Stutte HJ; Bleyl U; Schmitt M
    Histopathology; 2000 Jun; 36(6):499-504. PubMed ID: 10849091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
    Jelisavac-Cosic S; Sirotkovic-Skerlev M; Kulic A; Jakic-Razumovic J; Kovac Z; Vrbanec D
    Tumori; 2011; 97(4):532-9. PubMed ID: 21989445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
    Hildenbrand R; Glienke W; Magdolen V; Graeff H; Stutte HJ; Schmitt M
    Histochem Cell Biol; 1998 Jul; 110(1):27-32. PubMed ID: 9681686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
    Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
    Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
    Pusina S
    Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
    Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
    Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Boissière-Michot F; Mollevi C; Baecker V; Crapez E; Jacot W
    Int J Mol Med; 2022 Jun; 49(6):. PubMed ID: 35475537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
    Luparello C; Del Rosso M
    Eur J Cancer; 1996 Apr; 32A(4):702-7. PubMed ID: 8695276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.